Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (502)	11/9/2004 10:10:13 AM
From: tuck	Respond to of 625

Not a good day for CAT; now Trabio fails: >>CAMBRIDGE, England, Nov. 9 /PRNewswire-FirstCall/ -- Cambridge Antibody Technology (LSE: CAT - News; Nasdaq: CATG - News) today announces preliminary results from its first pivotal ('European' Phase II/III) clinical trial of Trabio®. The trial, which started in February 2002, was carried out in 344 patients in six European countries. On the basis of a preliminary analysis, Trabio has failed to meet the primary endpoint of improving the outcome of surgery for glaucoma compared to placebo. The preliminary analysis by itself does not support the filing of a Biologics Licence Application (BLA) in 2005. Data from a second pivotal ('International' Phase III) clinical trial of Trabio are expected in early 2005. CAT will provide further information with its Preliminary Results announcement on 22 November 2004. << snip Cheers, Tuck